Nov 5 (Reuters) - AstraZeneca, the British drugmaker working on one of the world’s leading COVID-19 vaccine candidates, on Thursday beat third-quarter sales estimates on strong demand for its diverse portfolio of drugs during COVID-19 pandemic lockdowns and maintained its 2020 forecasts.
Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.
Sign up for a free trial of our full service at https://www.breakingviews.com/trial and follow us on Twitter @Breakingviews and at www.breakingviews.com. All opinions expressed are those of the authors.